期刊
MABS
卷 15, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2023.2167189
关键词
CD137; 4-1BB; TNFRSF9; cancer immunotherapy; costimulatory agonist; 4-1BB agonists; bispecific antibodies
The clinical development of 4-1BB agonists for cancer immunotherapy has generated significant interest, but the first generation of agonistic antibodies failed due to toxicity or lack of efficacy. Second-generation 4-1BB agonists addressing the limitations of the first generation are now being developed and entering clinical studies. This review provides an overview of the differences between these agonists and the challenges in their clinical development.
The clinical development of 4-1BB agonists for cancer immunotherapy has raised substantial interest during the past decade. The first generation of 4-1BB agonistic antibodies entering the clinic, urelumab (BMS-663513) and utomilumab (PF-05082566), failed due to (liver) toxicity or lack of efficacy, respectively. The two antibodies display differences in the affinity and the 4-1BB receptor epitope recognition, as well as the isotype, which determines the Fc-gamma-receptor (Fc gamma R) crosslinking activity. Based on this experience a very diverse landscape of second-generation 4-1BB agonists addressing the liabilities of first-generation agonists has recently been developed, with many entering clinical Phase 1 and 2 studies. This review provides an overview focusing on differences and their scientific rationale, as well as challenges foreseen during the clinical development of these molecules.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据